Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond

Zhu, Yalan; Xu, Lingling; Kang, Yong; Cheng, Qinzhen; He, Yiling; Ji, Xiaoyuan

doi:10.1016/j.biomaterials.2024.122478

Cited by 9 publications

(1 citation statement)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, curcumin has limited bioavailability and is metabolized in the liver by aldo–keto reductase, in addition to having low water solubility (0.4 μg/mL at normal gastric pH 1.5–4.0) and limited BBB permeability. To solve these problems, various systems have been developed, including nanocarrier preparations for curcumin delivery, such as liposomes, micelles, solid lipid nanoparticles (SLNs), liquid crystalline nanoparticles (LCNs), polymeric nanoparticles, cell membrane nanocarriers, and cyclodestrin [ 27 , 28 , 29 ]. To determine the pharmacokinetics and pharmacodynamics of curcumin, Ravindranath and Chandrasekhara (1981, 1982) [ 30 , 31 ] administered 3 H-curcumin to rats, showing that curcumin undergoes several metabolic biochemical transformations.…”

Section: Curcumin: Bioavailability and Metabolismmentioning

confidence: 99%

Neuroprotective Effects of Curcumin in Neurodegenerative Diseases

Genchi,

Lauria,

Catalano

et al. 2024

Foods

View full text Add to dashboard Cite

Curcumin, a hydrophobic polyphenol extracted from the rhizome of Curcuma longa, is now considered a candidate drug for the treatment of neurological diseases, including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), Huntington’s Disease (HD), Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and prion disease, due to its potent anti-inflammatory, antioxidant potential, anticancerous, immunomodulatory, neuroprotective, antiproliferative, and antibacterial activities. Traditionally, curcumin has been used for medicinal and dietary purposes in Asia, India, and China. However, low water solubility, poor stability in the blood, high rate of metabolism, limited bioavailability, and little capability to cross the blood–brain barrier (BBB) have limited the clinical application of curcumin, despite the important pharmacological activities of this drug. A variety of nanocarriers, including liposomes, micelles, dendrimers, cubosome nanoparticles, polymer nanoparticles, and solid lipid nanoparticles have been developed with great success to effectively deliver the active drug to brain cells. Functionalization on the surface of nanoparticles with brain-specific ligands makes them target-specific, which should significantly improve bioavailability and reduce harmful effects. The aim of this review is to summarize the studies on curcumin and/or nanoparticles containing curcumin in the most common neurodegenerative diseases, highlighting the high neuroprotective potential of this nutraceutical.

show abstract

Section: Curcumin: Bioavailability and Metabolismmentioning

confidence: 99%

Neuroprotective Effects of Curcumin in Neurodegenerative Diseases

Genchi,

Lauria,

Catalano

et al. 2024

Foods

View full text Add to dashboard Cite

show abstract

Genetically Engineered Cellular Nanovesicles: Theories, Design and Perspective

Cheng,

Li,

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

The use of cellular nanovesicles (CNVs) is a groundbreaking innovation in biomedical applications. Both natural extracellular vesicles (EVs) and artificial cell membrane nanovesicles (AVs) have emerged as innovative CNVs, but they have limitations in therapeutic effects and targeting abilities. Challenges such as stability, immunogenicity, and drug payload capacity hinder their widespread application. Genetic engineering has matured as a widely employed modification strategy, leading to the development of genetically engineered extracellular vesicles (gEVs) and genetically engineered artificial cell membrane nanovesicles (gAVs). This review meticulously examines the diverse types and inherent characteristics of CNVs, alongside various surface engineering strategies for CNVs, with a specific focus on elucidating the attributes and detailing the preparation methods relevant to gEVs and gAVs. Furthermore, this exploration delves into the expansive landscape of biomedical applications, developmental prospects, and current challenges associated with the utilization of gEVs and gAVs. With a comprehensive approach, the primary objective is to provide insights that not only illuminate the nuanced intricacies of these nanovesicles but also pave the way for their seamless integration into clinical research and eventual translation into practical applications.

show abstract